| | Abbott ordains Elan to marry Tricor and Crestor |
 | | Elan's NanoCrystal technology can be utilised in a combination product to optimise bioavailability and absorption in patients, particularly of poorly water-soluble compounds, making it an attractive choice for Abbott and AstraZeneca, whose Tricor and Crestor respectively both treat adults with high cholesterol. |
 | | This is accomplished with NanoCrystal particles, which are typically less than 1,000 nanometres in diameter and are produced by milling the drug substance using Elan's wet-milling technique. |
 | | The NanoCrystal particles of the drug are stabilized against agglomeration by surface adsorption of selected GRAS (Generally Regarded As Safe) stabilisers, so the result is an aqueous dispersion of the drug substance that behaves like a solution, a NanoCrystal colloidal dispersion, which can be processed into finished dosage forms for all routes of administration. |
| www.drugresearcher.com /news/ng.asp?n=68996-abbott-elan-nanocrystal-tricor-crestor (851 words) |